Clinical trials
Secukinumab clinical trials
Below are recruiting secukinumab clinical trials, each written for real people, not researchers. We’re tracking 19 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05303285RecruitingPhase 4
Secukinumab for active ankylosing spondylitis in Chinese adults
This trial studies whether secukinumab (a targeted medicine given by injection) can reduce symptoms and disease activity in adults with active ankylosing spondylitis. You may be considered if other common anti-inflammatory medicines have not worked well enough or you could not take them.
Wuhan, HubeiAges 18–80 - NCT06926192Recruiting
Secukinumab plus surgery for moderate to severe hidradenitis suppurativa
This trial tests whether combining the drug secukinumab with surgery can help people with moderate to severe hidradenitis suppurativa (HS). It looks at how well this combination works and if it is safe over a year.
Nanjing, JiangsuAges Up to 80 years - NCT06751238RecruitingPhase 1
Secukinumab for children with psoriatic arthritis
This study tests a drug called secukinumab (given through an IV) in children with juvenile psoriatic arthritis. The goal is to see how well it works and if it's safe over time, for up to 6 years.
Loma Linda, CaliforniaAges 2–17 - NCT06905288Recruiting
Secukinumab for Ankylosing Spondylitis in Biologic-Free Patients
This study is looking at how well secukinumab works for people with ankylosing spondylitis in Korea who have never taken a biologic or JAK inhibitor before. It aims to understand if the drug helps control symptoms over a short period of time.
Jinju, Gyeongsangnam-doAges 18–40 - NCT04638647RecruitingPhase 4
Continue secukinumab after prior study, without safety issues
This trial lets people who already did a previous secukinumab (an injection for certain inflammatory conditions) study continue treatment afterward. It’s mainly for people who are still getting benefit and can’t otherwise get the approved medication through their local system.
Fullerton, CaliforniaAges 6–100 - NCT07489573RecruitingPhase 4
Study of secukinumab for Chinese adults with moderate-to-severe HS
This study tests if a drug called secukinumab (a self-injected biologic) is safe and effective for adults with moderate-to-severe hidradenitis suppurativa (HS) in China. It may help reduce the number of painful HS lesions.
Guangzhou, GuangdongAges 18 years+ - NCT06707246Recruiting
Comparing secukinumab and tofacitinib for hidradenitis suppurativa
This trial tests two medications, secukinumab and tofacitinib, to see which works better for moderate to severe hidradenitis suppurativa (a skin condition causing painful bumps) in Chinese patients. The goal is to find a more effective treatment option.
Hangzhou, ZhejiangAges 18–75 - NCT07109765Recruiting
Secukinumab for moderate to severe hidradenitis suppurativa
This study tests a drug called secukinumab (a type of biologic that targets inflammation) for people with moderate to severe hidradenitis suppurativa (HS). It may be an option if you have tried other treatments and they didn't work well.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07243782Recruiting
Study of Cosentyx for skin and joint conditions in Korea
This study tracks how well Cosentyx works in real-world use for people with hidradenitis suppurativa, plaque psoriasis, or juvenile idiopathic arthritis. It helps doctors understand the medicine's long-term effects in Korean patients.
Seoul, SeoulAges 6–100 - NCT07683065Recruiting
Secukinumab treatment in psoriasis patients with liver condition
This study looks at how well secukinumab works for psoriasis patients who also have a type of fatty liver disease called MASLD. It may help doctors understand if this treatment is a good option for people with both conditions.
Badalona, BarcelonaAges 18–100 - NCT06398106RecruitingPhase 4
Proactive monitoring vs. standard use of biologics for psoriasis
This study compares a proactive approach (adjusting drug levels based on regular blood tests) versus the usual way of using biologics for psoriasis. It helps see if active monitoring can improve treatment while keeping you safe.
BrugesAges 18 years+ - NCT07543419Recruiting
Real-world Study of Secukinumab for Moderate to Severe Hidradenitis Suppurativa
This study tracks how secukinumab (a new medication) works for hidradenitis suppurativa—a painful skin condition with recurring boils and abscesses—in real-world patient care in Italy. Researchers want to understand treatment patterns and outcomes to help improve care for this condition.
Ancona, ANAges 18–100 - NCT05503875Recruiting
Study uses psoriasis “immune patterns” to guide treatment
This study looks at immune system differences in people with moderate-to-severe psoriasis. It aims to help guide more precise (targeted) treatment choices and may improve how well treatment works for you.
Hangzhou, ZhejiangAges 18–75 - NCT07138898RecruitingPhase 2
Managing immune medications for shoulder replacement in rheumatology patients
This trial tests two ways of managing your immunosuppressant medication around the time of shoulder replacement surgery. The goal is to see if one approach leads to fewer infections while still controlling your rheumatic disease.
New York, New YorkAges 18 years+ - NCT06730334Recruiting
Psoriatic arthritis study using ultrasound to track activity
This study uses power Doppler ultrasound to classify and measure how active your psoriatic arthritis is. It may help doctors better understand and treat your condition.
Nanjing, JiangsuAges 18 years+ - NCT06786936Recruiting
Study of IL-17 in depression with psoriasis
This study explores whether a protein called IL-17 might link skin/joint inflammation with depressive symptoms. If you have psoriasis or psoriatic arthritis and are starting a specific biologic (secukinumab, bimekizumab, or ixekizumab), this could help understand how treatment affects your mood.
Glasgow, ScotlandAges 18–74 - NCT06987292Recruiting
Studying IL-17 inhibitors for hidden tendon inflammation in psoriasis
This study tests whether IL-17 inhibitor medications can reduce inflammation in tendons and ligaments that is not visible on the skin but can be detected with a special ultrasound. It may be an option for people with moderate to severe psoriasis who have not had enough relief from creams or light therapy.
Nanjing, JiangsuAges 18 years+ - NCT07237594RecruitingPhase 1
IL-17 blocker to prevent immunotherapy side effects
This trial tests whether a drug called secukinumab (an IL-17 blocker) can prevent or reduce severe side effects when you restart immunotherapy for advanced melanoma. It's for people who've had immune-related side effects before and need to continue treatment.
Durham, North CarolinaAges 18 years+ - NCT07282015Recruiting
Real-world study of secukinumab for HS in Canada
This study looks at how well secukinumab (Cosentyx) works in real life for people with moderate-to-severe hidradenitis suppurativa (HS) in Canada. If you're just starting this treatment, researchers want to track your progress and side effects.
Calgary, AlbertaAges 18–100
Hear when a new Secukinumab trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for secukinumab?
- Yes. Clin2 currently lists 19 recruiting secukinumab studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a secukinumab trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a secukinumab trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.